Sun Pharma Q4 Results 2026: Profit up 26% YoY

Key takeaway

Sun Pharmaceutical Industries reported a sharp year-on-year rise in profit for the March 2026 quarter, backed by growth in India formulations and performance across markets. The company also recommended a final dividend of ₹5 for FY26, while disclosing exceptional gains during the year.

What Sun Pharma reported for Q4 FY26

Sun Pharmaceutical Industries said its consolidated net profit for the fourth quarter of FY26 (January to March 2026) rose 26.24% year-on-year to ₹2,714.03 crore. The company had reported profit of ₹2,149.88 crore in the same quarter a year earlier.

Revenue for the quarter was reported at ₹14,612 crore, up 12.8% from ₹12,959 crore in the year-ago period. The company described the quarter’s performance as being supported by strong growth in its portfolio and healthy sales across markets.

Multiple reports described Sun Pharma as India’s largest drugmaker and linked the quarterly outcome to formulation sales momentum in India.

India formulations: growth and mix

Sun Pharma said India formulations recorded growth of 14.8% in Q4, led by the CVD, CNS, Gastro and Ortho segments. In absolute terms, formulation sales in India were ₹4,835.9 crore for the quarter.

The company also disclosed that India formulation sales accounted for 33.2% of total consolidated sales in Q4. That mix is closely watched by investors because domestic formulation growth can influence the stability of quarterly revenue, particularly when other geographies face pricing pressure or regulatory changes.

Management commentary and market-share cue

In the full-year context, Sun Pharmaceutical Industries Managing Director Kirti Ganorkar said the company’s performance reflected “several significant achievements.” He highlighted that Sun’s 0.3 percentage point gain in the India market was its highest gain since the Ranbaxy acquisition.

The statement is notable because it frames the FY26 execution in the domestic market as an explicit market-share outcome rather than only a growth-rate headline. It also signals management’s focus on India as a strategic pillar alongside international operations.

FY26 full-year numbers

For the full financial year FY26, Sun Pharma reported net profit of ₹11,479.4 crore, up 5%. Sales for FY26 were ₹58,220.1 crore, up 11.9% year-on-year.

These numbers provide context for the Q4 outcome. A 26% jump in quarterly profit can coincide with a lower full-year growth rate when earlier quarters had different cost trends, tax impacts, or one-off items that change the year’s base.

Exceptional gains disclosed in FY26

Sun Pharma reported exceptional gains of approximately ₹1,700 crore in FY26. This included exceptional items worth ₹1,307.5 crore and an exceptional tax credit of ₹385.4 crore for the year ended March 31, 2026.

Exceptional items can affect how investors compare “reported” profit across periods, especially when these items do not recur. The company’s disclosure helps readers separate underlying operating performance from one-time or non-operating factors.

Dividend: final payout proposed for FY26

Alongside the results, Sun Pharma recommended a final dividend of ₹5 for FY26. Dividend recommendations are typically tracked for signals on cash generation, capital allocation priorities, and board confidence in near-term cash flows.

The company’s announcement adds a shareholder-return element to the results season narrative, particularly for long-term investors who evaluate dividend consistency.

Estimates check and how the quarter landed

One report noted profits at ₹2,714 crore versus estimates of ₹2,762 crore. While the company still delivered a strong year-on-year increase, this comparison shows the reported number was slightly below the cited estimate.

For the market, such gaps can shape the immediate reaction in the stock price, even when the year-on-year growth looks strong. The direction of revenue growth and the quality of profit drivers often determine whether the market treats the “miss” as material.

Key numbers at a glance

Market impact and investor takeaways

The headline numbers combine two signals that investors typically focus on: faster growth in Q4 profit and a clear sales increase for the quarter. The disclosed rise in India formulations and the share of India in consolidated sales underscore the role of the domestic market in Sun Pharma’s quarterly performance.

At the same time, the disclosure of exceptional gains in FY26 is central to interpreting full-year profitability. When exceptional items and tax credits are significant, investors often compare reported profits with underlying trends in revenue and segment performance, and they watch subsequent quarters for consistency.

Conclusion

Sun Pharma’s Q4 FY26 results showed a 26.2% rise in net profit to ₹2,714.03 crore and revenue growth to ₹14,612 crore, alongside a ₹5 final dividend recommendation for FY26. Investors will track how India formulations growth, market-share gains, and the role of exceptional items shape reported performance in coming quarters.